NEWS RELEASE

Glaukos Technologies Featured in Podium and Poster Presentations at 2015 American Academy of Ophthalmology

11/9/2015

Surgeons to Present Recent Personal Experience Data and Clinical Results at Annual American Medical Conference

LAS VEGAS--(BUSINESS WIRE)-- **Glaukos Corporation** (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, announced today that its products will be featured in several presentations and courses at the annual American Academy of Ophthalmology (AAO) meeting being held in Las Vegas, Nevada on November 14 – 17, 2015. In addition, Glaukos will host a major symposium on Saturday evening, November 14th.

The American Academy of Ophthalmology is the largest national membership organization of ophthalmologists who provide comprehensive eye care to patients throughout the world. More than 90 percent of practicing ophthalmologists are AAO members, and the Academy boasts of more than 7,000 international members.

Topics by Day and Time (Pacific Standard Time):

Saturday, November 14, 2015

1. 5:30 – 7:30 pm
   MIGS Symposium
   Faculty: Richard Lindstrom, MD; Ike Ahmed, MD; John Berdahl, MD; Edward Holland, MD; Thomas Samuelson, MD
   Location: Paris Hotel, Meeting Room Champagne (Rooms 3 and 4), 3655 S. Las Vegas Blvd.

Sunday, November 15, 2015

2. 12:30 – 2:00 pm
   Fritz Hengerer, MD – Personal Experience with Second Generation Trabecular Micro-Bypass Stents in Open-Angle Glaucoma
   Location: Sands Expo/Venetian, Hall G
3. 2:00 - 4:15 pm
   Brian Francis, MD – Ab Interno Approach to the Schlemm Canal
   Location: Sands Expo/Venetian, Marco Polo 701

Monday, November 16, 2015

4. 7:30 – 8:30 am
   Reay Brown, MD – Adding MIGS (iStent) to Your Cataract
   Location: Sands Expo/Venetian, Hall G

Glaukos pioneered micro-invasive glaucoma surgery (MIGS), which involves the insertion of a micro-scale device from within the eye's anterior chamber through a small corneal incision. The MIGS device reduces intraocular pressure by restoring the natural outflow pathways for aqueous humor. In 2012, Glaukos received U.S. Food & Drug Administration (FDA) approval and launched its first MIGS device, the iStent®, which has been shown to lower intraocular pressure (IOP) in adult patients with mild-to-moderate open-angle glaucoma undergoing cataract surgery.

The company's next-generation MIGS device, the iStent inject®Trabecular Micro-Bypass Stent includes two stents preloaded in an auto-injection mechanism that allows an ophthalmic surgeon to inject stents into multiple trabecular meshwork locations through a single corneal entry point. The iStent inject has been approved in the European Union, Australia and Canada. Glaukos has also developed the iStent Supra® Suprachoroidal Micro-Bypass Stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye and is approved in the European Union. The company has IDE clinical trials underway in the United States for two versions of the iStent inject, one for use in conjunction with cataract surgery and another for use in a standalone procedure. A U.S. IDE clinical trial is also underway for the iStent Supra device.

Glaukos at AAO

Glaukos will exhibit on the showroom floor at the Sands Expo convention center in Las Vegas, Nevada from November 14 – 17, 2015 at booth #439.

About iStent® Trabecular Micro-Bypass

Indication for Use: The iStent® Trabecular Micro-Bypass Stent is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild-to-moderate open-angle glaucoma currently treated with ocular hypotensive medication.

Contraindications: The iStent® is contraindicated in eyes with primary or secondary angle closure glaucoma, including neovascular glaucoma, as well as in patients with retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.

Warnings: Gonioscopy should be performed prior to surgery to exclude PAS, rubeosis, and other angle abnormalities or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard. The iStent® is MR-Conditional meaning that the device is safe for use in a specified MR environment under specified conditions, please see label for details.

Precautions: The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. The safety and effectiveness of the iStent® has not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, chronic inflammation, or an abnormal anterior segment, in pseudophakic patients with glaucoma, in patients with pseudoexfoliative glaucoma, pigmentary, and uveitic glaucoma, in patients with unmedicated IOP less than 22 mmHg or greater than 36 mmHg after “washout” of medications, or in patients with prior glaucoma surgery of any type including argon laser trabeculoplasty, for implantation of more than a single stent, after complications during cataract surgery, and when implantation has been without concomitant cataract surgery with IOL implantation for visually significant cataract.

Adverse Events: The most common post-operative adverse events reported in the randomized pivotal trial included early post-operative corneal edema (8%), BCVA loss of = 1 line at or after the 3 month visit (7%), posterior capsular opacification (6%), stent obstruction (4%) early post-operative anterior chamber cells (3%), and early post-operative corneal abrasion (3%). Please refer to Directions for Use for additional adverse event information.

Caution: Federal law restricts this device to sale by, or on the order of, a physician. Please reference the Directions for Use labeling for a complete list of contraindications, warnings, precautions, and adverse events.

About Glaukos Corporation

Glaukos is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. The company believes the iStent, measuring 1.0 mm long and 0.33 mm wide, is the smallest medical

device ever approved by the FDA. (**www.glaukos.com**)

Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These include statements about our plans, objectives, strategies and prospects regarding, among other things, our current product, pipeline technology and corresponding efforts to secure regulatory approvals. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Therefore, they may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law. The known risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission and available in the Investor section of our website at **www.glaukos.com** and at **www.sec.gov**.

View source version on businesswire.com: **http://www.businesswire.com/news/home/20151109005458/en/**

Source: Glaukos Corporation

Media Contact:

for Glaukos Corporation

Cassandra Dump, 1.619.971.1887

Cassy@pascalecommunications.com

or

Investor Contact:

Glaukos Corporation

Sheree Aronson, 1.949-367.9600 Ext. 371

saronson@glaukos.com